Reteplase

Reteplase is a recombinant non-glycosylated form of human tissue plasminogen activator, used as thrombolytic agent.

Indications

Acute ST-elevation myocardial infarction (STEMI).

Dosage

IV; As soon as possible after the onset of STEMI, administer 10 units intravenously over 2 minutes. Administer a second dose of 10 units 30 minutes after the first dose. Reconstitute with sterile water supplied with it.

Contra-Indications

Active internal bleeding, Recent stroke, Intracranial or intraspinal surgery or serious head trauma within 3 months, Intracranial conditions that increase the risk of bleeding (e.g. neoplasms, arteriovenous malformation, or aneurysms), Bleeding diathesis, Current severe uncontrolled hypertension.

Special Precautions

Do not administer along with heparin intravenous line. Paediatric: Safety and efficacy in pediatric patients have not been established. Pregnancy: In animal studies it is associated with increased birth defects and miscarriage. Lactation: Data not sufficient. Elderly: Use with caution.

Side Effects

Bleeding, hypersensitivity, cholesterol embolisation.

Drug Interactions

Data not sufficient.